SCHEDULE 13G/A: Rosalind Advisors and Affiliates Maintain 9.9% Beneficial Stake in Biofrontera Inc. Common Stock

Rosalind Advisors, Inc. and its affiliates, including Rosalind Master Fund L.P., reported a continued beneficial ownership of 9.9% of Biofrontera Inc.'s common stock as of December 31, 2024, primarily through common shares, preferred shares, and convertible debt, subject to a 9.99% blocker provision.

Summary

• Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon collectively reported beneficial ownership of 9,962,649 shares of Biofrontera Inc. common stock as of December 31, 2024.
• This represents 9.9% of the class, calculated based on 8,873,932 common shares outstanding as of January 15, 2025, as reported by Biofrontera Inc. in its S1 filing on January 17, 2025.
• The reported beneficial ownership includes 811,918 shares of existing common stock, 6,586,629 shares issuable upon exercise of preferred shares, and 2,564,102 shares issuable upon exercise of convertible debt.
• A 'blocker provision' limits the exercise of preferred shares and convertible debt such that the holder's beneficial ownership does not exceed 9.99% of the common stock.
• Due to this blocker, the Reporting Persons were not able to exercise any of the preferred shares or convertible debt as of the filing date, meaning their actual beneficial ownership of common stock was limited to 811,918 shares, representing approximately 9.15%.
• The filing is an Amendment No. 4 to a Schedule 13G, indicating a passive investment intent.

Sentiment

Score: 5

Explanation: Neutral. The document is a factual disclosure of beneficial ownership, indicating a continued significant stake by an institutional investor. The 'blocker' provision is a standard anti-dilution or ownership limit clause, not inherently positive or negative in terms of sentiment, but it clarifies the immediate exercisable common stock.

Positives

• A significant institutional investor group maintains a substantial stake in Biofrontera Inc., potentially signaling long-term confidence.

Negatives

• The 'blocker provision' limits the immediate conversion of preferred shares and convertible debt into common stock, potentially restricting the investor's ability to increase their direct common stock holding beyond 9.99% at any given time.

Risks

• The existence of a significant amount of preferred shares and convertible debt that could be converted into common stock (totaling 9,150,731 shares if not for the blocker) represents potential future dilution for existing common shareholders if the blocker is removed or the company's share count increases significantly.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a significant passive investment by Rosalind Advisors and its affiliates in Biofrontera Inc., a common practice for institutional investors seeking exposure to specific companies within the biotechnology or pharmaceutical sector. The presence of convertible securities suggests a prior financing arrangement, typical for growth-stage companies in this industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake and the limitations on their immediate conversion rights due to a blocker provision.

Key Dates

Keywords

Biofrontera Inc., Common Shares, Schedule 13G, Beneficial Ownership, Rosalind Advisors, Rosalind Master Fund, Institutional Investor, Preferred Shares, Convertible Debt, Blocker Provision, SEC Filing